Yposkesi Acquisition Fuels SK's Global Push Into Biologics Manufacturing
Adds Gene, Cell Therapy Capabilities
South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.
You may also be interested in...
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.
With its COVID-19 vaccine development project nearing the finish line, SK Bioscience unveils an ambitious growth strategy which includes mergers and acquisitions and diversification into the cell and gene therapy sector.